

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM815034

| | | | |
|---|-------------------------------------|-------------------------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | MERGER | | |
| EFFECTIVE DATE: | 03/31/2023 | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Concert Pharmaceuticals, Inc. | | 03/28/2023 | Corporation: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | Sun Pharmaceutical Industries, Inc. | | |
| Street Address: | 2 Independence Way | | |
| City: | Princeton | | |
| State/Country: | NEW JERSEY | | |
| Postal Code: | 08540 | | |
| Entity Type: | Corporation: DELAWARE | | |
| PROPERTY NUMBERS Total: 8 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 97638190 | CONCERT PHARMACEUTICALS INC. | |
| Serial Number: | 97638152 | CONCERT PHARMACEUTICALS INC. | |
| Serial Number: | 97638112 | PRODUCT INNOVATION. PATIENT IMPACT. | |
| Serial Number: | 90505049 | LEQSELVI | |
| Serial Number: | 90505282 | TIDASVIQ | |
| Serial Number: | 88247527 | C | |
| Serial Number: | 86597389 | CONCERT PHARMACEUTICALS INC. | |
| Serial Number: | 86597360 | CONCERT PHARMACEUTICALS INC. | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 6173109177 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 617-439-2177 | | |
| Email: | pconcannon@nutter.com | | |
| Correspondent Name: | Patrick J. Concannon | | |
| Address Line 1: | Nutter, McClennen & Fish, LLP | | |
| Address Line 2: | Seaport West, 155 Seaport Boulevard | | |
| Address Line 4: | Boston, MASSACHUSETTS 02210 | | |
| ATTORNEY DOCKET NUMBER: | 116013-1 | | |

OP \$215.00 97638190

| | |
|--|----------------------|
| NAME OF SUBMITTER: | Patrick J. Concannon |
| SIGNATURE: | /PJC/ |
| DATE SIGNED: | 06/05/2023 |
| Total Attachments: 3 source=Concert-Sun Pharma Certificate of Merger#page1.tif source=Concert-Sun Pharma Certificate of Merger#page2.tif source=Concert-Sun Pharma Certificate of Merger#page3.tif | |

Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"CONCERT PHARMACEUTICALS, INC.", A DELAWARE CORPORATION, WITH AND INTO "SUN PHARMACEUTICAL INDUSTRIES, INC." UNDER THE NAME OF "SUN PHARMACEUTICAL INDUSTRIES, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTY-EIGHTH DAY OF MARCH, A.D. 2023, AT 6:22 O`CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE THIRTY-FIRST DAY OF MARCH, A.D. 2023 AT 12:01 O'CLOCK A.M.




Jeffrey W. Bullock, Secretary of State

7893212 8100M
SR# 20231190441

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 203035584
Date: 03-29-23

TRADEMARK
REEL: 008091 FRAME: 0659

**CERTIFICATE OF MERGER
OF
CONCERT PHARMACEUTICALS, INC.
WITH AND INTO
SUN PHARMACEUTICAL INDUSTRIES, INC.**

March 28, 2023

Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware (the “**DGCL**”), Sun Pharmaceutical Industries, Inc., a corporation organized and existing under the DGCL, does hereby certify that:

FIRST: The names and states of incorporation of each of the constituent corporations in the Merger (as defined below) are as follows:

- (a) Sun Pharmaceutical Industries, Inc., a Delaware corporation (the “**Company**”), and
- (b) Concert Pharmaceuticals, Inc., a Delaware corporation (“**Concert**”).

SECOND: The Agreement and Plan of Merger, dated as of March 28, 2023 (the “**Merger Agreement**”), by and among Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation, the Company and Concert, pursuant to which Concert will merge with and into the Company, with the Company surviving as the surviving corporation (the “**Merger**”), has been approved, adopted, executed and acknowledged by each of the Company and Concert in accordance with the requirements of Section 251 of the DGCL.

THIRD: Following the Merger, the Company will continue its existence as the surviving corporation and the separate corporate existence of Concert will cease. The name of the surviving corporation shall be Sun Pharmaceutical Industries, Inc. (the “**Surviving Corporation**”).

FOURTH: The certificate of incorporation of the Company, as in effect immediately prior to the Merger, shall be the certificate of incorporation of the Surviving Corporation.

FIFTH: The Merger is to become effective as of 12:01 a.m., Eastern Time, on March 31, 2023.

SIXTH: The executed Merger Agreement is on file at the principal place of business of the Surviving Corporation. The address of said principal place of business is 2 Independence Way, Princeton, New Jersey 08540.

SEVENTH: An executed copy of the Merger Agreement will be furnished by the Surviving Corporation on request and without cost to any stockholder of the Company or Concert.

[Remainder of page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, the Company has caused this Certificate of Merger to be executed by its duly authorized officer as of the date first written above.

SUN PHARMACEUTICAL INDUSTRIES, INC.

DocuSigned by:

By: 89D5E76E2482457
Name: Abhay Gandhi
Title: Chief Executive Officer

[Signature Page to Certificate of Merger]